This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, G. W. Search for Related Content PubMed PubMed Citation Articles by Stone, G. W.

(Circulation. 1998;97:2482-2485.)
© 1998 American Heart Association, Inc.

Editorials

Primary Stenting in Acute Myocardial Infarction

The Promise and the Proof

Gregg W. Stone, MD

From The Cardiovascular Institute, Mountain View, Calif.

Key Words: Editorials • stents • myocardial infarction • angioplasty • trials

With the demonstration that the timely administration of thrombolytic therapy after coronary arterial occlusion results in myocardial salvage and improved survival, the treatment of patients with evolving AMI has forever been changed. To overcome the inherent limitations of thrombolytic therapy (TIMI 3 flow rates of 55% at best, and rare but unavoidable life-threatening or incapacitating hemorrhagic complications), mechanical reperfusion by balloon angioplasty without antecedent thrombolysis (primary PTCA) has been adopted at many centers. Ten prospective, randomized trials comparing primary PTCA and lytic therapy in 2606 patients have now been performed and examined in a recent meta-analysis by Weaver et al,¹ demonstrating that compared with thrombolytic therapy, primary PTCA results in reduced rates of mortality, reinfarction, and stroke. Other randomized trials^{2 3} have shown that primary PTCA, by reducing early and late recurrent ischemic events and facilitating earlier discharge, is as or more cost-effective than thrombolysis.

Despite these attributes, balloon-induced medial disruption and platelet activation result in recurrent ischemia in 10% to 15% of patients treated with primary PTCA before hospital discharge, including reinfarction in 3% to 5% of patients.⁴ Although improvements in operator technique, exclusive use of ionic contrast, and attention to anticoagulation status can minimize these complications,⁵ the significant residual stenosis remaining in many patients after balloon angioplasty, in concert with intimal hyperplasia, unopposed vessel recoil, and late remodeling, results in angiographic restenosis in 30% to 50% of infarct vessels within 6 months.⁴ As a result, 20% of patients after primary PTCA require TVR with repeat angioplasty or bypass surgery . . . [Full Text of this Article]

This article has been cited by other articles:

				I. Herz, A. Assali, A. Solodky, N. Shor, T. Ben-Gal, Y. Adler, and Y. Birnbaum Coronary Stent Deployment Without Predilation in Acute Myocardial Infarction: A Feasible, Safe, and Effective Technique Angiology, November 1, 1999; 50(11): 901 - 908. [Abstract] [PDF]

				T. J. Ryan, E. M. Antman, N. H. Brooks, R. M. Califf, L. D. Hillis, L. F. Hiratzka, E. Rapaport, B. Riegel, R. O. Russell, E. E. Smith III, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J. Am. Coll. Cardiol., September 1, 1999; 34(3): 890 - 911. [Full Text] [PDF]